Patient Enrollment for AspenBio Pharma, Inc.'s FDA 510(k) Clinical Trial for AppyScore(TM), World’s First Appendicitis Blood Test, Nearing Halfway Point

CASTLE ROCK, CO--(Marketwire - September 04, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, reported enrollment levels are approaching fifty percent in the ongoing FDA 510(k) clinical trial for AppyScore™, the world's first blood-based diagnostic tool for human appendicitis.